On Tuesday, Shares of QUALCOMM, Inc. (NASDAQ:QCOM), lost -0.49% to $62.80.
Qualcomm Incorporated, declared a quarterly cash dividend of $0.48 per common share, payable on September 23, 2015, to stockholders of record at the close of business on September 2, 2015.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States.
Shares of Amdocs Limited (NASDAQ:DOX), declined -1.11% to $54.44, during its last trading session.
Amdocs Limited, declared it has accomplished the divestiture of its BSS business unit to Amdocs (DOX) for a purchase price of about $273 million. Comverse will now be singularly focused on growing its global market leadership in digital services.
Amdocs Limited provides software and services for communications, media, and entertainment industry service providers worldwide. It offers revenue administration products that address BSS/OSS data processing and event-handling needs, in addition to provides automated partner administration and settlement for various types of partners, counting interconnect, content, roaming, digital advertising, mobile virtual network operator, wholesale, and dealer.
Finally, St. Jude Medical, Inc. (NYSE:STJ), ended its last trade with 1.38% gain, and closed at $74.06.
St. Jude Medical, declared the launch of the ILUMIEN III clinical trial, a prospective, international, randomized trial evaluating the clinical benefits of the company’s optical coherence tomography (OCT) guidance during stent implantation. The ILUMIEN III study will compare OCT-guided stent implantation to implantation guided by intravascular ultrasound (IVUS) or angiography alone, diagnostic tools that offer less resolution than OCT during intravascular assessments and percutaneous coronary intervention (PCI).
The ILUMIEN III study is the largest multicenter randomized study to date to compare PCI outcomes associated with all three imaging tools. By assessing each diagnostic system head-to-head, the study should offer clear insight into OCT’s ability to influence clinical outcomes.
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
